Cathy Perry is an experienced professional in clinical development and leadership within the biopharmaceutical industry. Currently serving as a Team Leader at Genentech since 2020, Cathy is engaged in foundational aspects of a new field. Previously, from 2017 to 2019, Cathy played a significant role in Merck's leadership team, spearheading the implementation of histopathology-based technologies across various therapeutic areas such as diabetes and oncology. As Director of Clinical Development at Portola Pharmaceuticals from 2015 to 2017, Cathy oversaw the development of a P2Y12 inhibitor for acute coronary syndrome. Additionally, Cathy's earlier tenure at CV Therapeutics from 2011 to 2014 involved leading the global Phase 2 and Phase 3 development of Regadenoson, which received U.S. approval. Cathy holds a Master's degree in Molecular and Cellular Biology from the University of North Carolina at Chapel Hill.
This person is not in the org chart
This person is not in any teams
This person is not in any offices